The UCI Chao Family Comprehensive Cancer Center (CFCCC) has been selected to join the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network (ETCTN). This network is part of the NCI Division of Cancer Treatment & Diagnosis program for conducting cooperative early-phase clinical trials in cancer and a major accomplishment for our institution.
The CFCCC was originally selected in 2020 as one of 13 NCI cancer center sites nationally to receive a supplement to our P30 Cancer Center support grant called CATCH-UP, for targeted enrollment of under-represented minorities to ETCTN trials. Based on our staff’s outstanding work and accrual to CATCH-UP, the cancer center is now one of 13 centers selected to formally join the ETCTN.
The ECTN network is comprised of 33 sites across the US and Canada that develop novel NCI-Investigational New Drug (IND) anticancer agents alone or in combination within biomarker-rich phase 1 and phase 2 clinical trials.